Crinetics Pharmaceuticals Announced Topline Results From PATHFNDR-2 Phase 3 Trial Of Paltusotine For Acromegaly Achieving The Primary And All Secondary Endpoints; NDA Submission To FDA Expected In 2H 2024
Portfolio Pulse from Benzinga Newsdesk
Crinetics Pharmaceuticals announced successful topline results from its PATHFNDR-2 Phase 3 trial of Paltusotine for Acromegaly, achieving the primary and all secondary endpoints. The company expects to submit a New Drug Application (NDA) to the FDA in the second half of 2024.

March 19, 2024 | 10:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crinetics Pharmaceuticals' successful Phase 3 trial results for Paltusotine in treating Acromegaly and the planned NDA submission to the FDA could significantly boost investor confidence.
The successful completion of the Phase 3 trial and the achievement of all primary and secondary endpoints for Paltusotine in treating Acromegaly are critical milestones for Crinetics Pharmaceuticals. These results not only validate the efficacy of the drug but also pave the way for its commercialization, subject to FDA approval. The announcement of an expected NDA submission in the second half of 2024 further solidifies the company's timeline towards bringing the drug to market. Given these developments, investor confidence in CRNX is likely to increase, potentially leading to a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100